Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that generics erosion, particularly for best-selling beta blockers and angiotensin-converting enzyme inhibitors, will result in slow market growth for the treatment of chronic heart failure.

The new Pharmacor report entitled Chronic Heart Failure finds that recent guidelines recommending more widespread use of beta blockers should spur near- term increased sales of carvedilol, GlaxoSmithKline's Coreg and Roche's Dilatrend, as well as metoprolol succinate, AstraZeneca's Toprol XL. However, overall market growth will be offset by patent expiries including the expiration of ramipril, Wyeth/King's Altace and Sanofi-Aventis's Tritace, which will strongly contribute to a loss in the angiotensin-converting enzyme inhibitors market share by 2014. Although there is intense research activity for new chronic heart failure therapies, the report reveals that a weak late- stage pipeline will also limit market expansion.

"Novel therapies that better target the pathogenesis of chronic heart failure are still very much in demand but the outlook for the launch of such a treatment during our 2004 to 2014 study period is bleak," said Nikhil Mehta, analyst at Decision Resources, Inc. "Significant opportunity remains for companies exploring novel compounds in early stages of drug development, such as those now being studied to address cardiac remodeling and inflammation in chronic heart failure."

About Chronic Heart Failure

Twenty percent of all hospital admissions for people 65 and older is caused by chronic heart failure and, despite a plethora of available treatments, the prognosis for patients remains poor.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs currently on the market and in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Indianapolis's Unregulated Hospital Market Continues Its Building Boom, According To HealthLeaders-InterStudy

View Now